First, as a novel oral inhibitor, lenvatinib simultaneously suppresses the activity of factors involved in tumor angiogenesis while also suppressing tumor proliferation signals via the VEGF and FGF receptors [22, 23]. Here, VEGFA is linked to neoplasm.